Synairgen plc (LON:SNG – Get Rating) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 19.75 ($0.24) and traded as low as GBX 12.50 ($0.15). Synairgen shares last traded at GBX 13.85 ($0.17), with a volume of 1,251,966 shares traded.
Synairgen Stock Performance
The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.35. The stock has a market cap of £27.89 million and a PE ratio of -0.57. The company's 50 day simple moving average is GBX 15.51 and its 200 day simple moving average is GBX 19.75.
Synairgen Company Profile
(Get Rating)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Read More
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
在周五的交易中,Synairgen plc(伦敦股票代码:SNG-GET Rating)的股价跌破了200日移动均线。该股的200日移动均线为19.75英镑(合0.24美元),交易价格低至12.50英镑(合0.15美元)。Synairgen的股票最后交易价格为13.85英镑(0.17美元),总成交量为1,251,966股。
Synairgen股票表现
该公司的负债权益比率为0.09,速动比率为6.35,流动比率为6.35。该股市值2789万GB,市盈率为-0.57。该公司的50日简单移动均线切入位在15.51,200日简单移动均线切入位在19.75.
Synairgen公司简介
(获取评级)
Synairgen plc发现和开发治疗呼吸系统疾病的药物。该公司开发的产品有:治疗新冠肺炎的乙型吸入型干扰素SG001;治疗感冒和流感引起的哮喘的乙型干扰素吸入剂;治疗或预防慢性阻塞性肺病的乙型干扰素第二阶段临床试验;以及治疗特发性肺纤维化的LXL2抑制剂。
阅读更多内容
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升,提振销售观点
- KLA公司:在动荡不安的半市场中站稳脚跟
接受Synairgen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synairgen和相关公司的最新新闻和分析师评级的每日简明摘要。